» Articles » PMID: 35898125

Failure or Relapse Predictors for the STREAM Stage 1 Short Regimen for RR-TB

Overview
Specialty Pulmonary Medicine
Date 2022 Jul 28
PMID 35898125
Authors
Affiliations
Soon will be listed here.
Abstract

STREAM (Standardised Treatment Regimens of Anti-tuberculosis drugs for Multidrug-Resistant Tuberculosis) Stage 1 demonstrated non-inferior efficacy of a short regimen for rifampicin-resistant TB (RR-TB) compared to a long regimen as recommended by the WHO. The present paper analyses factors associated with a definite or probable failure or relapse (FoR) event in participants receiving the Short regimen. This analysis is restricted to 253 participants allocated to the Short regimen and is based on the protocol-defined modified intention to treat (mITT) population. Multivariable Cox regression models were built using backwards elimination with an exit probability of = 0.157, equivalent to the Akaike Information Criterion, to identify factors independently associated with a definite or probable FoR event. Four baseline factors were identified as being significantly associated with the risk of definite or probable FoR (male sex, a heavily positive baseline smear grade, HIV co-infection and the presence of costophrenic obliteration). There was evidence of association of culture positivity at Week 8 and FoR in a second model and Week 16 smear positivity, presence of diabetes and of smoking in a third model. The factors associated with FoR outcomes identified in this analysis should be considered when determining the optimal shortened treatment regimen.

Citing Articles

At Long Last: Short, All-Oral Regimens for Multidrug-Resistant Tuberculosis in the United States.

Sinha P, Jacobson K, Horsburgh Jr C, Acuna-Villaorduna C Open Forum Infect Dis. 2023; 10(4):ofad177.

PMID: 37125228 PMC: 10135426. DOI: 10.1093/ofid/ofad177.

References
1.
Yadav A, Mehrotra A, Agnihotri S, Swami S . Study of factors influencing response and outcome of Cat-IV regimen in MDRTB patients. Indian J Tuberc. 2016; 63(4):255-261. DOI: 10.1016/j.ijtb.2016.09.013. View

2.
Elliott E, Draper H, Baitsiwe P, Claassens M . Factors affecting treatment outcomes in drug-resistant tuberculosis cases in the Northern Cape, South Africa. Public Health Action. 2015; 4(3):201-3. PMC: 4533815. DOI: 10.5588/pha.14.0029. View

3.
Magis-Escurra C, Gunther G, Lange C, Alexandru S, Altet N, Avsar K . Treatment outcomes of MDR-TB and HIV co-infection in Europe. Eur Respir J. 2017; 49(6). DOI: 10.1183/13993003.02363-2016. View

4.
Bisson G, Bastos M, Campbell J, Bang D, Brust J, Isaakidis P . Mortality in adults with multidrug-resistant tuberculosis and HIV by antiretroviral therapy and tuberculosis drug use: an individual patient data meta-analysis. Lancet. 2020; 396(10248):402-411. PMC: 8094110. DOI: 10.1016/S0140-6736(20)31316-7. View

5.
Schwoebel V, Trebucq A, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J . Outcomes of a nine-month regimen for rifampicin-resistant tuberculosis up to 24 months after treatment completion in nine African countries. EClinicalMedicine. 2020; 20:100268. PMC: 7152829. DOI: 10.1016/j.eclinm.2020.100268. View